- Home
- CCM vs LPCN Comparison
CCM vs LPCN Comparison
Compare CCM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- LPCN
- Stock Information
- Founded
- CCM 1997
- LPCN 1997
- Country
- CCM China
- LPCN United States
- Employees
- CCM N/A
- LPCN N/A
- Industry
- CCM Medical/Nursing Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- LPCN Health Care
- Exchange
- CCM Nasdaq
- LPCN Nasdaq
- Market Cap
- CCM 18.2M
- LPCN 16.1M
- IPO Year
- CCM 2009
- LPCN N/A
- Fundamental
- Price
- CCM $4.73
- LPCN $3.10
- Analyst Decision
- CCM
- LPCN Strong Buy
- Analyst Count
- CCM 0
- LPCN 1
- Target Price
- CCM N/A
- LPCN $10.00
- AVG Volume (30 Days)
- CCM 29.8K
- LPCN 10.3K
- Earning Date
- CCM 05-02-2025
- LPCN 05-08-2025
- Dividend Yield
- CCM N/A
- LPCN N/A
- EPS Growth
- CCM N/A
- LPCN N/A
- EPS
- CCM N/A
- LPCN N/A
- Revenue
- CCM $64,910,622.00
- LPCN $11,198,144.00
- Revenue This Year
- CCM N/A
- LPCN N/A
- Revenue Next Year
- CCM N/A
- LPCN N/A
- P/E Ratio
- CCM N/A
- LPCN N/A
- Revenue Growth
- CCM N/A
- LPCN N/A
- 52 Week Low
- CCM $3.80
- LPCN $2.75
- 52 Week High
- CCM $26.70
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- CCM 58.04
- LPCN 46.56
- Support Level
- CCM $3.88
- LPCN $2.82
- Resistance Level
- CCM $4.55
- LPCN $3.27
- Average True Range (ATR)
- CCM 0.39
- LPCN 0.23
- MACD
- CCM 0.07
- LPCN 0.01
- Stochastic Oscillator
- CCM 84.16
- LPCN 58.92
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.